REVAMP Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jun 28, 2018)
Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act
This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a "priority antimicrobial product." (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)
What just happenedJun 28, 2018
Referred to the House Committee on Energy and Commerce.
Who’s behind it
- Introduced in HouseJun 28, 2018
- Jun 28, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jun 28, 2018IntroReferralIntro-H
Introduced in House
- Jun 28, 2018IntroReferral1000
Introduced in House